Role of full-length osteoprotegerin in tumor cell biology

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cellular and Molecular Life Sciences

• Publication date

  2009-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00018-008-8536-xPMID 19011755PMCID PMC11131453
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis.

  2008cited by this paper
• Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.

  2008cited by this paper
• Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway

  2008cited by this paper
• Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis

  2008cited by this paper
• OPG Is Regulated by β-Catenin and Mediates Resistance to TRAIL-Induced Apoptosis in Colon Cancer

  2008cited by this paper
• Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells.

  2008cited by this paper
• Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation.

  2008cited by this paper
• A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer

  2008cited by this paper
• Heparin-regulated delivery of osteoprotegerin promotes vascularization of implanted hydrogels

  2008cited by this paper
• Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

  2008cited by this paper
• The role of myeloid cells in the promotion of tumour angiogenesis

  2008cited by this paper
• The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review.

  2008cited by this paper
• Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

  2008cited by this paper
• Osteoprotegrin and the bone homing and colonization potential of breast cancer cells

  2008cited by this paper
• TRAIL inhibits osteoclastic differentiation by counteracting RANKL‐dependent p27Kip1 accumulation in pre‐osteoclast precursors

  2008cited by this paper
• Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells.

  2008cited by this paper
• Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2.

  2007cited by this paper
• Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.

  2007cited by this paper
• The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis

  2007cited by this paper
• Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3

  2007cited by this paper
• MDM2 Antagonist Nutlin‐3 Suppresses the Proliferation and Differentiation of Human Pre‐Osteoclasts Through a p53‐Dependent Pathway

  2007cited by this paper
• The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: Implications for association studies with human cancers

  2007cited by this paper
• The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts.

  2007cited by this paper
• Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.

  2007cited by this paper
• Human Fanconi A cells are susceptible to TRAIL‐induced apoptosis

  2007cited by this paper
• Characterization of the interaction between von Willebrand factor and osteoprotegerin

  2007cited by this paper
• Clinical development of anti-RANKL therapy

  2007cited by this paper
• MDM2 inhibitors for cancer therapy.

  2007cited by this paper
• Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.

  2007cited by this paper
• Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo.

  2007cited by this paper
• Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro.

  2007cited by this paper
• B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo.

  2007cited by this paper
• Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.

  2007cited by this paper
• An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.

  2006cited by this paper
• Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

  2006cited by this paper
• Osteoprotegerin and Bone Mass in Squamous Cell Head and Neck Cancer Patients

  2006cited by this paper
• Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.

  2006cited by this paper
• Remodeling and Vascular Spaces in Bone

  2006cited by this paper
• Antianoikis Effect of Nuclear Factor-κB through Up-regulated Expression of Osteoprotegerin, BCL-2, and IAP-1*

  2006cited by this paper
• Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.

  2006cited by this paper
• A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients.

  2006cited by this paper
• Osteoprotegerin (OPG)—a potential new role in the regulation of endothelialcell phenotype and tumour angiogenesis?

  2006cited by this paper
• The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology.

  2006cited by this paper
• Role of osteoprotegerin (OPG) in cancer.

  2006cited by this paper
• Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α

  2005cited by this paper
• Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

  2005cited by this paper
• Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.

  2005cited by this paper
• Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes.

  2005cited by this paper
• Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes.

  2005cited by this paper
• Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand*

  2005cited by this paper
• Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies1

  2005cited by this paper
• TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release.

  2005cited by this paper
• Osteoprotegerin is expressed in colon carcinoma cells.

  2005cited by this paper
• Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis

  2004cited by this paper
• TRAIL regulates normal erythroid maturation through an ERK-dependent pathway.

  2004cited by this paper
• The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival.

  2004cited by this paper
• Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer

  2004cited by this paper
• Disabling of Receptor Activator of Nuclear Factor-κB (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo*

  2004cited by this paper
• Heparan Sulfate Proteoglycans Function as Receptors for Fibroblast Growth Factor-2 Activation of Extracellular Signal–Regulated Kinases 1 and 2

  2004cited by this paper
• TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.

  2004cited by this paper
• IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.

  2004cited by this paper
• The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.

  2004cited by this paper
• Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications

  2004cited by this paper
• Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen

  2004cited by this paper
• Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma

  2004cited by this paper
• Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma

  2003cited by this paper
• Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.

  2003cited by this paper
• Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls.

  2003cited by this paper
• Expression of osteoprotegerin mRNA and protein in murine megakaryocytes.

  2003cited by this paper
• Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.

  2003cited by this paper
• Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

  2003cited by this paper
• TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways

  2003cited by this paper
• Tumor Necrosis Factor‐Related Apoptosis‐Inducing Ligand (TRAIL) Sequentially Upregulates Nitric Oxide and Prostanoid Production in Primary Human Endothelial Cells

  2003cited by this paper
• Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.

  2003cited by this paper
• Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1

  2002cited by this paper
• A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function.

  2002cited by this paper
• Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway.

  2002cited by this paper
• Osteoprotegerin deficiency and juvenile Paget's disease.

  2002cited by this paper
• Characterization of the in vivo function of TNF‐α‐related apoptosis‐inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene‐deficient mice

  2002cited by this paper
• Serum osteoprotegerin levels in healthy controls and cancer patients.

  2002cited by this paper
• Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells.

  2002cited by this paper
• Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

  2002cited by this paper
• A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype.

  2002cited by this paper
• Cancellous Bone Remodeling Occurs in Specialized Compartments Lined by Cells Expressing Osteoblastic Markers

  2001cited by this paper
• Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.

  2001cited by this paper
• Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

  2001cited by this paper
• The death domain superfamily: a tale of two interfaces?

  2001cited by this paper
• Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis*

  2001cited by this paper
• Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.

  2001cited by this paper
• Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.

  2001cited by this paper
• Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)--mediated cytotoxicity by selective up-regulation of TRAIL-R1.

  2001cited by this paper
• Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

  2001cited by this paper
• Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells.

  2000cited by this paper
• Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.

  2000cited by this paper
• Temperature-sensitive Differential Affinity of TRAIL for Its Receptors

  2000cited by this paper
• The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.

  2000cited by this paper
• Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells*

  2000cited by this paper
• The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated* *This work was supported by Grant AG-04875 from the National Institute on Aging.

  2000cited by this paper
• Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

  2000cited by this paper
• Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors

  1999cited by this paper

• Repositioning the Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) on the TRAIL to the Development of Diabetes Mellitus: An Update of Experimental and Clinical Evidence

  2022cites this paper
• Engagement of TRAIL triggers degranulation and IFNγ production in human natural killer cells

  2022cites this paper
• Anti-Tumoral Effect of Chemerin on Ovarian Cancer Cell Lines Mediated by Activation of Interferon Alpha Response

  2022cites this paper
• Osteoprotegerin interacts with syndecan-1 to promote human endometrial stromal decidualization by decreasing Akt phosphorylation.

  2020cites this paper
• OSTEOPROTEGERIN INJECTION INDUCES MORPHOLOGICAL AND FUNCTIONAL ALTERATIONS IN MOUSE PANCREATIC ISLETS

  2020influential citation
• Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy

  2020cites this paper
• The immune system on the TRAIL of Alzheimer’s disease

  2020cites this paper
• TNFRSF11B: A potential plasma biomarker for diagnosis of obstructive sleep apnea.

  2019cites this paper
• Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic Retinopathy

  2018cites this paper
• Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages.

  2018cites this paper
• RANKL, OPG, TRAIL, KRas, and c-Fos expression in relation to central lymph node metastases in papillary thyroid carcinoma.

  2018cites this paper
• New insights into the role of Methionine 199 in the function of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and bone homeostasis

  2018cites this paper
• From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease

  2017cites this paper
• Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy.

  2017cites this paper
• Osteoprotegerin rich tumor microenvironment: implications in breast cancer

  2016cites this paper
• Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease

  2016cites this paper
• The Janus Face of Death Receptor Signaling during Tumor Immunoediting

  2016cites this paper
• Clinical perspectives of TRAIL: insights into central nervous system disorders

  2016cites this paper
• Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity.

  2016cites this paper
• Two-dimensional gel electrophoresis analysis of the leiomyoma interstitial fluid reveals altered protein expression with a possible involvement in pathogenesis.

  2015cites this paper
• SHORT COMMUNICATION Osteoprotegerin Protects against Muscular Dystrophy

  2015cites this paper
• OPG‐Fc inhibits ovariectomy‐induced growth of disseminated breast cancer cells in bone

  2015cites this paper
• Osteoprotegerin protects against muscular dystrophy.

  2015cites this paper
• Osteoprotegerin in breast cancer: beyond bone remodeling

  2015cites this paper
• TRAIL Modulates the Immune System and Protects against the Development of Diabetes

  2015influential citation
• A potential osteoporosis target in the FAS ligand/FAS pathway of osteoblast to osteoclast signaling.

  2015influential citation
• Osteoprotegerin expression in triple-negative breast cancer cells promotes metastasis

  2014cites this paper
• The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias

  2014influential citation
• Modulation of Circulating Cytokine-Chemokine Profile in Patients Affected by Chronic Venous Insufficiency Undergoing Surgical Hemodynamic Correction

  2014cites this paper
• NF-κB pathways in hematological malignancies

  2014cites this paper
• Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival.

  2014cites this paper
• Heterogeneity of mesenchymal stromal cells in lymphoproliferative disorders.

  2014cites this paper
• RANKL Inhibitors Induce Osteonecrosis of the Jaw in Mice With Periapical Disease

  2014influential citation
• Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.

  2014cites this paper
• Levels of circulating TNF-related apoptosis-inducing ligand in celiac disease

  2014cites this paper
• Rola osteoprotegeryny w patogenezie zaburzeń gospodarki wapniowo-fosforanowej i metabolizmu kostnego w przewlekłej chorobie nerek

  2014cites this paper
• Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells.

  2013cites this paper
• Transglutaminase-2 Is Involved in Expression of Osteoprotegerin in MG-63 Osteosarcoma Cells

  2013influential citation
• TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.

  2013cites this paper
• MDM2 non-genotoxic inhibitors as innovative therapeutic approaches for the treatment of pediatric malignancies.

  2013cites this paper
• L’ostéoprotégérine, nouvel acteur dans l’angiogenèse : Rôle dans la formation de nouveaux vaisseaux et mécanisme d’action

  2013influential citation
• RANKL employs distinct binding modes to engage RANK and the OPG decoy receptor

  2013cites this paper
• Rab25 Small GTPase Mediates Secretion of Tumor Necrosis Factor Receptor Superfamily Member 11b (osteoprotegerin) Protecting Cancer Cells from Effects of TRAIL

  2013influential citation
• Targeting apoptosis pathways in glioblastoma.

  2013cites this paper
• GM-CSF Exhibits Anti-Inflammatory Activity on Endothelial Cells Derived from Chronic Venous Disease Patients

  2013cites this paper
• Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.

  2013influential citation
• Differential expression and tumor necrosis factor‐mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas

  2013cites this paper
• RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor.

  2012cites this paper
• State of the art of the therapeutic perspective of sorafenib against hematological malignancies.

  2012cites this paper
• Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells.

  2012cites this paper
• Potential role of TRAIL in the management of autoimmune diabetes mellitus.

  2012cites this paper
• Endothelial Cells Obtained from Patients Affected by Chronic Venous Disease Exhibit a Pro-Inflammatory Phenotype

  2012cites this paper
• Early pregnancy Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR 8 trophoblastic cells

  2012influential citation
• Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines

  2012cites this paper
• State of art and recent developments of anti-cancer strategies based on TRAIL.

  2012cites this paper
• A mechanobiological model of orthodontic tooth movement

  2012cites this paper
• Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells

  2012cites this paper
• In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody

  2012cites this paper
• Therapeutic targeting of CD95 and the TRAIL death receptors.

  2011cites this paper
• Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice.

  2011cites this paper
• Molecular targets for selective killing of TRAIL-resistant leukemic cells

  2011cites this paper
• Recent advances in the therapeutic perspectives of Nutlin-3.

  2011cites this paper
• Clinical Significance of Osteoprotegerin Expression in Human Colorectal Cancer

  2011cites this paper
• Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop.

  2011cites this paper
• Infantile haemangioma expresses tumour necrosis factor‐related apoptosis‐inducing ligand (TRAIL), TRAIL receptors, osteoprotegerin and receptor activator for nuclear factor кB ligand (RANKL) †

  2011cites this paper
• Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets.

  2011cites this paper
• Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony‐forming cells properties

  2011cites this paper
• microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis.

  2011influential citation
• APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.

  2011cites this paper
• Trail down‐regulates the release of osteoprotegerin (OPG) by primary stromal cells

  2011cites this paper
• Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells

  2010cites this paper
• B cell receptor triggering sensitizes human B cells to TRAIL‐induced apoptosis

  2010cites this paper
• Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis.

  2010cites this paper
• Interleukin-6 Increases Expression and Secretion of Cathepsin B by Breast Tumor-Associated Monocytes

  2010cites this paper
• New paradigms in cell death in human diabetic nephropathy.

  2010cites this paper
• ESTUDO DA IMUNOEXPRESSÃO DE RANKL E OPG, DO ÍNDICE ANGIOGÊNICO (CD34) E DA PRESENÇA DE MIOFIBROBLASTOS (α-SMA) EM CERATOCISTOS ODONTOGÊNICOS ISOLADOS E ASSOCIADOS À

  2010cites this paper
• TNF-α modulates the migratory response of mesenchymal stem cells to TRAIL

  2010cites this paper
• A Genetically Encoded Multifunctional TRAIL Trimer Facilitates Cell-Specific Targeting and Tumor Cell Killing

  2010cites this paper
• Dexamethasone counteracts the anti‐osteoclastic, but not the anti‐leukemic, activity of TNF‐related apoptosis inducing ligand (TRAIL)

  2010cites this paper
• RANK/RANKL/OPG role in distraction osteogenesis.

  2010cites this paper